Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS6422 with Capecitabine in Advanced or Metastatic Breast Cancer
NCT06568692Phase 2Terminated
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PCS6422 in breast cancer, sponsored by Processa Pharmaceuticals, Inc.. Started Oct 2024; status: terminated.
02
Drugs
PCS6422
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06568692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568692.